HOME >> BIOLOGY >> NEWS
Temple engineers recieve NSF grant to develop interactive high school biology curriculum

To help high-school students better understand and apply scientific methodologies to biology problems, the Intelligent Systems Application Center (ISAC) in Temple's College of Engineering has been awarded a three-year, $843,000 grant by the National Science Foundation to develop three intelligent, interactive, multimedia modules for use in high-school biology curriculums.

Building on the popularity of the CSI television programs, the Interactive Virtual Intelligent System for Scientific Inquiry in a Biology Learning Environment (INVISSIBLE) will involve students by having them investigate a murder crime scene, the Thomas Jefferson-Sally Hemings genealogy debate, and the origin theory of Homo sapiens.

"We want students to learn that there are different ways of applying a scientific method," said Brian P. Butz, director of ISAC and principal investigator on the NSF grant. "For example, we want them to understand that you don't have to have a laboratory with experiments, where you take those experiments and you analyze them, build a hypothesis from them and try to replicate the data.

Using INVISSIBLE, students will interact in the three scenarios that reflect the authentic experiences of a scientist engaged in using scientific inquiry methods. The students must use scientific inquiry skills and reasoning patterns necessary for the reconstruction of past events, said Butz, who is a professor of electrical and computer engineering at Temple.

The first scenario presents students with a murder investigation where they are charged with the responsibility of identifying suspects and solving the crime. Identifying suspects is analogous to generating multiple working hypotheses. According to Butz, his module will introduce students to the procedures of evidence-gathering and analysis used by scientists who study past events, but it will do so in a context that is likely to be familiar to students.

In the second scenario, Butz said, students will be e
'"/>

Contact: Preston M. Moretz
pmoretz@temple.edu
215-204-7476
Temple University
7-Jun-2005


Page: 1 2 3

Related biology news :

1. Third annual Templeton-Cambridge Fellowships awarded to 10 noted journalists
2. John Templeton Foundation awards $2.8 million to examine origins of biological complexity
3. SHRO signs agreement with Temple to continue biomedical research
4. Temple virologist receives $6.1 million NIH grant for neuro-AIDS research
5. Temple University researchers develop new targeted cancer therapy
6. Boston Univeristy bioengineers devise dimmer swith to regulate gene expression in mammal cells
7. Worlds top engineers in San Antonio for system of systems conference
8. New medications, cancer diagnosis goals of UH engineers with $1M in grants
9. EO Lawrence Award goes to 8 scientists and engineers
10. Carnegie Mellon engineers devise new process to improve energy efficiency of ethanol production
11. Pittsburgh-based team engineers muscle, bone cell differentiation with aid of ink-jet printer

Post Your Comments:
(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: